Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial

William W. Busse, Elliot Israel, Harold S. Nelson, James W. Baker, B. Lauren Charous, Donald Y. Young, Vladimir Vexler, Richard S. Shames, J. Baker, G. Bensch, W. Berger, R. Berkowitz, S. Brazinsky, W. Busse, B. L. Charous, P. Chervinsky, J. Corren, T. Craig, P. Goldberg, G. GrossE. Israel, H. Kaiser, K. Kirn, P. Korenblat, E. Lisberg, M. Liu, A. Nayak, H. Nelson, A. Pedinoff, S. Weakley

Research output: Contribution to journalArticlepeer-review

130 Scopus citations

Abstract

Rationale: Airway inflammation in asthma is associated with increased activated CD25+ T cells, IL-2, and soluble IL-2 receptors (IL-2Rs). Objectives: A randomized, double-blinded, placebo-controlled study was used to evaluate the safety and efficacy of daclizumab, a humanized IgG1 monoclonal antibody against the IL-2R α chain (CD25) of activated lymphocytes, in adults with moderate to severe persistent asthma. Methods: Patients with obstructive pulmonary functions, despite inhaled corticosteroids (ICS), were switched to equivalent dose inhaled triamcinolone acetate acetonide (TAA). Patients dependent on ICS were randomized (3:1) to daclizumab (intravenous loading dose, 2 mg/kg, then 1 mg/kg) or placebo every 2 weeks, added to stable-dose TAA through Week 12 (Treatment Period 1). Over Weeks 12-20 (Treatment Period 2), patients tapered TAA while on the study drug, and were followed for 16 weeks off the study drug. Measurements and Main Results: Among 115 evaluable patients (88 daclizumab, 27 placebo), groups had similar age, disease duration, and length of ICS use. During Treatment Period 1, daclizumab improved FEV1 (daclizumab, 4.4 ± 1.80% vs. placebo, 1.5 ± 2.39%; P = 0.05), and reduced daytime asthma symptoms (P = 0.018) and short-acting inhaled β2-agonist use (P = 0.009). Daclizumab treatment prolonged time to exacerbation (P = 0.024). Adverse events were evenly distributed between groups, although there were more serious adverse events in the patients treated with daclizumab. Conclusions: Daclizumab improved pulmonary function and asthma control in patients with moderate to severe chronic asthma inadequately controlled on ICS. The mechanism of action likely involves inhibition of proinflammatory cytokine generation by IL-2R blockade in activated T cells. Clinical trial registered with www.clinicaltrials.gov (NCT00028288).

Original languageEnglish (US)
Pages (from-to)1002-1008
Number of pages7
JournalAmerican journal of respiratory and critical care medicine
Volume178
Issue number10
DOIs
StatePublished - Nov 15 2008

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial'. Together they form a unique fingerprint.

Cite this